Diagnostic and Prognostic Value of cfDNA Concentration and Fragmentation in Prostate Cancer
The Prostate · 2026
DOI: 10.1002/pros.70090 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2026. Verfasst von Marta Victoria Lorenzo-Sánchez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hospital and University Complex of Albacete, Albacete, Spain. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biomarkers, Tumor, Cell-Free Nucleic Acids, DNA Fragmentation. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To evaluate the value of circulating free DNA (cfDNA) in prostate cancer (PCa) by cfDNA assay and analysis of plasma and urinary cfDNA fragmentation to determine the usefulness of this parameter for risk staging and tumor progression monitoring. Materials and Methods A prospective, longitudinal study was conducted with 143 individuals, including a control group and a cohort of patients with PCa at different stages: localized, metastatic hormone‐sensitive (mHSPC), and metastatic castration‐resistant (mCRPC). Plasma and urine samples were collected to measure the concentration, fluorescence units (FU), and cfDNA fragmentation, correlating them with clinical and pathological variables.
Results
Plasma cfDNA levels were higher in patients with PCa than in control subjects (14.3 ng/mL vs. 4.2 ng/mL, p = 0.04) and even higher in metastatic disease than in localized (20.8 ng/mL vs. 3.6 ng/mL, p < 0.001). The fragmentation size of plasma cfDNA was smaller in metastatic PCa (168.7 base pairs) than in localized PCa (172.8 base pairs, p < 0.001), suggesting that shorter fragments are associated with more aggressive disease. Following systemic treatment, the patients decreased cfDNA levels (8.3 ng/mL vs. 4.9 ng/mL, p = 0.027) and plasma FU (35.2 vs. 12.9, p < 0.001). In urine, differences were only observed in patients who progressed to CRPC than in those who remained HSPC (261.8 ng/mL vs. 43.5 ng/mL, p = 0.046).
Conclusions
The assay and analysis of plasma and urinary cfDNA fragmentation may provide useful biomarkers for PCa diagnosis and follow‐up, particularly when differentiating between localized and metastatic disease. These findings are promising, but further research is required to determine their potential utility in clinical risk stratification and treatment monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Hospital and University Complex of Albacete, Albacete, Spain.
- Experimental Research Unit, Hospital and University Complex of Albacete, Albacete, Spain.
- Department of Urology, General Hospital of Hellín, Albacete, Spain.
- School of Medicine of Albacete, Universidad de Castilla la Mancha, Albacete, Spain.
ORCID-Profile: Antonio Santiago Salinas-Sánchez
Zitieren
APA
Lorenzo-Sánchez, M. V., Giménez-Bachs, J. M., Picazo-Martínez, M. G., Donate-Moreno, M. J., Martínez-Sánchiz, C., Tárraga-Honrubia, M. A., Navarro-Jiménez, S., Legido-Gómez, Ó., & Salinas-Sánchez, A. S. (2026). Diagnostic and Prognostic Value of cfDNA Concentration and Fragmentation in Prostate Cancer. The Prostate. https://doi.org/10.1002/pros.70090
Vancouver
Lorenzo-Sánchez MV, Giménez-Bachs JM, Picazo-Martínez MG, Donate-Moreno MJ, Martínez-Sánchiz C, Tárraga-Honrubia MA, et al. Diagnostic and Prognostic Value of cfDNA Concentration and Fragmentation in Prostate Cancer. The Prostate. 2026. doi:10.1002/pros.70090
BibTeX
@article{LorenzoSnchez2026,
author = {Lorenzo-Sánchez, Marta Victoria and Giménez-Bachs, José Miguel and Picazo-Martínez, María Granada and Donate-Moreno, María José and Martínez-Sánchiz, Carlos and Tárraga-Honrubia, María Amalia and Navarro-Jiménez, Sonsoles and Legido-Gómez, Óscar and Salinas-Sánchez, Antonio Santiago},
title = {Diagnostic and Prognostic Value of cfDNA Concentration and Fragmentation in Prostate Cancer},
journal = {The Prostate},
year = {2026},
doi = {10.1002/pros.70090}
}
EUVIMED